US FDA Approves Glenmark’s Ryaltris for Children Aged 6 and Older

MUMBAI, India — Glenmark Pharmaceuticals Limited, a global research-led pharmaceutical enterprise, has received approval from the U.S. Food and Drug Administration (FDA) to expand the indication of its proprietary combination nasal spray, Ryaltris, to include pediatric patients aged 6 to under 12 years.

The regulatory milestone permits the commercial distribution of Ryaltris (olopatadine hydrochloride and mometasone furoate monohydrate) for the treatment of seasonal allergic rhinitis (SAR) in both adults and pediatric patients aged 6 years and older. Prior to this supplemental approval, the fixed-dose combination prescription treatment was restricted in the United States to adults and adolescents aged 12 years and above.

Technical Specifications and Dosage Mechanism

Ryaltris is a fixed-dose combination nasal spray that delivers a dual-action mechanism of action by combining an antihistamine and a corticosteroid. Each metered spray administers olopatadine hydrochloride (an H1-receptor inhibitor) alongside mometasone furoate monohydrate (an anti-inflammatory corticosteroid).

For pediatric patients aged 6 to 11 years, the recommended clinical dosage is one spray in each nostril twice daily. For adults and adolescents aged 12 and older, the established regimen remains two sprays per nostril twice daily.

Clinical Trial Background and Safety Profile

The approval expansion is supported by data from Phase 3 pediatric clinical trials designed to evaluate safety, tolerability, and efficacy in younger populations.

• Efficacy Metrics: In randomized, double-blind trials comparing Ryaltris against a placebo, pediatric patients aged 6 to under 12 exhibited statistically significant reductions in morning and evening Reflective Total Nasal Symptom Scores (rTNSS).

• Safety Evaluation: Treatment-emergent adverse events (TEAEs) were consistent with the established safety profile seen in adult trials, showing low incidence rates comparable to placebo controls.

• Growth Monitoring: As with all intranasal corticosteroids, prescribing guidelines advise routine monitoring of growth velocity in pediatric patients undergoing extended treatment regimens.

Market Dynamics and Corporate Impact

According to regulatory filings submitted to the National Stock Exchange of India (NSE) and BSE Limited, expanding the pediatric label significantly strengthens Glenmark's specialty respiratory franchise in North America.

Pediatric allergic rhinitis accounts for millions of clinical visits annually in the U.S. By offering a single-spray solution that replaces the need for separate antihistamine and steroid prescriptions, Glenmark aims to capture additional market share in pediatric respiratory care. The commercialization and distribution in the U.S. market are managed directly via its wholly owned subsidiary, Glenmark Pharmaceuticals Inc., USA.

Official Declarations

In statements documented through stock exchange disclosures and corporate communications, company management underscored the importance of pediatric-specific clinical research.

"According to officials, generating dedicated pediatric data was essential to confirm the safety and dosing parameters for younger patients. The expansion validates the clinical profile of Ryaltris and addresses a critical treatment gap for pediatric seasonal allergic rhinitis in the United States."

Why It Matters

• For Patients and Parents: Provides a simplified, dual-action treatment option in a single nasal spray, reducing pill burden and simplifying daily administration for school-aged children.

• For Healthcare Providers: Gives pediatricians and allergists an FDA-approved fixed-dose combination alternative when monotherapy fails to manage moderate-to-severe seasonal allergy symptoms.

• For Investors: Expands the addressable patient population for Glenmark’s branded respiratory pipeline in the high-value U.S. pharmaceutical market.

Key Facts at a Glance

• Product Name: Ryaltris (olopatadine hydrochloride and mometasone furoate monohydrate) Nasal Spray.

• Developer / Distributor: Glenmark Pharmaceuticals Inc., USA.

• Regulatory Action: U.S. FDA indication expansion for pediatric patients aged 6 to under 12 years.

• Therapeutic Indication: Treatment of symptoms associated with seasonal allergic rhinitis (SAR).

• Pediatric Dosing: One spray in each nostril twice daily.

Frequently Asked Questions (FAQ)

What is Ryaltris used for?

Ryaltris is a prescription nasal spray indicated for the treatment of symptoms associated with seasonal allergic rhinitis (SAR), such as nasal congestion, sneezing, runny nose, and nasal itching.

What age group is now approved to use Ryaltris in the U.S.?

Ryaltris is approved by the U.S. FDA for adults and pediatric patients aged 6 years and older.

How does Ryaltris differ from single-ingredient allergy sprays?

Ryaltris combines two active ingredients into a single nasal spray: an antihistamine (olopatadine) that blocks symptom-triggering histamines and a corticosteroid (mometasone) that reduces nasal tissue inflammation.

Source: Official regulatory disclosures and press releases issued by Glenmark Pharmaceuticals, clinical trial filings with the U.S. Food and Drug Administration (FDA), and corporate stock exchange submissions on the National Stock Exchange of India (NSE) and BSE Limited.